PT862622E - Metodo de rastreio para compostos que interagem com proteina cinase rac - Google Patents

Metodo de rastreio para compostos que interagem com proteina cinase rac

Info

Publication number: PT862622E
Authority: PT; Portugal
Prior art keywords: rac; screening; compounds; protein kinase; protein
Prior art date: 1995-11-16

Application number

PT96938081T

Other languages

English (en)

Inventor

Brian Arthur Hemmings

Cohen Philip

Alessi Dario

Cross Darren

Andjelkovic Mirjana

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-16

Filing date

1996-11-05

Publication date

2005-01-31

1995-11-16 Priority claimed from GBGB9523379.7A external-priority patent/GB9523379D0/en

1995-12-15 Priority claimed from GBGB9525704.4A external-priority patent/GB9525704D0/en

1996-11-05 Application filed by Novartis Ag filed Critical Novartis Ag

2005-01-31 Publication of PT862622E publication Critical patent/PT862622E/pt

Links

238000012216 screening Methods 0.000 title abstract 4
150000001875 compounds Chemical class 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 abstract 6
108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 abstract 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
230000005856 abnormality Effects 0.000 abstract 1
239000012190 activator Substances 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000003993 interaction Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Hematology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
General Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Microbiology (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

PT96938081T 1995-11-16 1996-11-05 Metodo de rastreio para compostos que interagem com proteina cinase rac PT862622E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9523379.7A GB9523379D0 (en)	1995-11-16	1995-11-16	Compound and method
GBGB9525704.4A GB9525704D0 (en)	1995-12-15	1995-12-15	Ligand and screening method

Publications (1)

Publication Number	Publication Date
PT862622E true PT862622E (pt)	2005-01-31

Family

ID=26308124

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT96938081T PT862622E (pt)	1995-11-16	1996-11-05	Metodo de rastreio para compostos que interagem com proteina cinase rac

Country Status (9)

Country	Link
EP (1)	EP0862622B1 (pt)
JP (1)	JP4173544B2 (pt)
AT (1)	ATE274053T1 (pt)
AU (1)	AU7564396A (pt)
DE (1)	DE69633186T2 (pt)
DK (1)	DK0862622T3 (pt)
ES (1)	ES2227614T3 (pt)
PT (1)	PT862622E (pt)
WO (1)	WO1997018303A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9525703D0 (en) *	1995-12-15	1996-02-14	Ciba Geigy Ag	Screening method
US6057117A (en) *	1996-04-04	2000-05-02	Chiron Corporation	Identification and use of selective inhibitors of glycogen synthase kinase 3
CA2214841A1 (en) *	1997-10-31	1999-04-30	Lisa Mckerracher	Rho antagonists and their use to block inhibition of neurite outgrowth
SE9801530D0 (sv) *	1998-04-30	1998-04-30	Pharmacia & Upjohn Ab	Method for screening
US6555732B1 (en)	1998-09-14	2003-04-29	Pioneer Hi-Bred International, Inc.	Rac-like genes and methods of use
WO2000023476A1 (en) *	1998-10-16	2000-04-27	Otsuka Pharmaceutical Co., Ltd.	Neovascular-specific peptides
US7169783B2 (en)	1998-11-02	2007-01-30	Universite De Montreal	(+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
GB9828375D0 (en) *	1998-12-22	1999-02-17	Janssen Pharmaceutica Nv	Human akt-3
WO2000050452A1 (en) *	1999-02-26	2000-08-31	University College London	Mutants of rac protein
US6881555B2 (en)	1999-03-19	2005-04-19	Aventis Pharmaceuticals Inc.	AKT nucleic acids, polypeptides, and uses thereof
PT1144600E (pt) *	1999-03-19	2008-10-10	Aventis Pharma Inc	Ácidos nucleicos akt-3, polipeptídeos e as suas utilizações
ATE397060T1 (de) *	2000-05-30	2008-06-15	Moelling Karin Inst Fuer Med V	Nukleinsäure moleküle kodierend für ein protein, welches mit einer ser/thr akt kinase interagiert
US6689807B1 (en)	2000-06-08	2004-02-10	Caritas St. Elizabeth's Medical Center Of Boston, Inc.	HMG CoA reductase inhibitors for promoting angiogenesis
GB0014185D0 (en) *	2000-06-09	2000-08-02	Novartis Res Found	Compound and method
AU2003284981B2 (en)	2002-10-30	2009-05-28	Merck Sharp & Dohme Corp.	Inhibitors of Akt activity
GB0227562D0 (en)	2002-11-26	2002-12-31	Novartis Forschungsstiftung	Phorphorylated NDR Kinase
AU2005287169A1 (en) *	2004-09-17	2006-03-30	Exelixis, Inc.	PIK4CA as modifier of the RAC pathway and methods of use
US9833431B2 (en) *	2013-11-01	2017-12-05	Pitney Pharmaceuticals Pty Limited	Pharmaceutical combinations for the treatment of cancer

1996
- 1996-11-05 EP EP96938081A patent/EP0862622B1/en not_active Expired - Lifetime
- 1996-11-05 DE DE69633186T patent/DE69633186T2/de not_active Expired - Lifetime
- 1996-11-05 ES ES96938081T patent/ES2227614T3/es not_active Expired - Lifetime
- 1996-11-05 WO PCT/EP1996/004810 patent/WO1997018303A1/en not_active Ceased
- 1996-11-05 PT PT96938081T patent/PT862622E/pt unknown
- 1996-11-05 AT AT96938081T patent/ATE274053T1/de active
- 1996-11-05 JP JP51854697A patent/JP4173544B2/ja not_active Expired - Lifetime
- 1996-11-05 DK DK96938081T patent/DK0862622T3/da active
- 1996-11-05 AU AU75643/96A patent/AU7564396A/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2227614T3 (es)	2005-04-01
EP0862622A1 (en)	1998-09-09
DE69633186T2 (de)	2005-08-18
DE69633186D1 (de)	2004-09-23
JP2000500746A (ja)	2000-01-25
DK0862622T3 (da)	2004-12-20
EP0862622B1 (en)	2004-08-18
WO1997018303A1 (en)	1997-05-22
AU7564396A (en)	1997-06-05
JP4173544B2 (ja)	2008-10-29
ATE274053T1 (de)	2004-09-15

Publication	Publication Date	Title
PT862622E (pt)	2005-01-31	Metodo de rastreio para compostos que interagem com proteina cinase rac
Hishikawa et al.	1997	Pulsatile stretch stimulates superoxide production and activates nuclear factor-κB in human coronary smooth muscle
Rangaswami et al.	2004	Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IκBα kinase-dependent nuclear factor κB-mediated promatrix metalloproteinase-9 activation
MX9606404A (es)	1998-01-31	Composiciones farmaceuticas y metodos para formular trasnduccion de señales.
DE69635671D1 (de)	2006-02-02	Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
ATE234092T1 (de)	2003-03-15	2-alkylpyrrolidine
PT1143955E (pt)	2005-11-30	Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
IS7770A (is)	2005-03-23	Hlutleysandi mótefni gegn GDF-8 og notkun theirra
DE69738739D1 (de)	2008-07-10	Verfahren für das Entwerfen von kleinen Erythropoietin Mimetika
DE69841434D1 (de)	2010-02-25	VERWENDUNG VON FVIIa ODER FVIIAi ZUR BEHANDLUNG VON ENDOTHELIALER FEHLFUNKTION BZW ZUR INHIBIERUNG DER ANGIOGENESE
DE69736351D1 (de)	2006-08-31	Methoden und mittel zur hemmung der cdk4-aktivität
GB9924957D0 (en)	1999-12-22	Novel treatment
EP0830139A4 (en)	2001-10-10	MODIFIED MYELIN PROTEIN MOLECULES
WO2000034511A3 (de)	2000-11-16	Peptid screening test zum nachweis von ass
DK0507831T3 (da)	1995-10-09	Fremgangsmåde til detektion af knogle- og bindevævssygdomme hos mennesker og dyr
BR0010007A (pt)	2002-01-15	Indicadores biológicos para validação de um processo de esterilização de prìon
AU4711597A (en)	1998-05-11	Diagnosis of spongiform encephalopathy
DK1169058T3 (da)	2007-09-10	Insulinlignende vækstfaktorbindingsprotein-4-protease
Ritchie et al.	2001	Characterization of crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI‐2)
BR9305035A (pt)	1994-06-21	Agentes de curtimento e sua aplicaçáo
WO2004109290A3 (en)	2005-03-24	Methods for identifying modulators of kinesin activity
DK1095032T3 (da)	2004-03-29	Hidtil ukendte fluorescerende CYP2D-assayreagenser
ATE278014T1 (de)	2004-10-15	Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
WO2002014536A3 (en)	2003-01-30	Odulating multiple lineage kinase proteins
WO2003012102A3 (fr)	2004-04-08	Acides nucleiques codant des proteines a domaine hect